Cardiac angiotensin II receptors as predictors of transplant coronary artery disease following heart transplantation.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  European Heart Journal

• Publication date

  2004-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.EHJ.2004.01.005PMID 15033249
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of Angiotensin Converting Enzyme Inhibitor Versus Angiotensin II Receptor Blocker

  2005cited by this paper
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.

  2003cited by this paper
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.

  2003cited by this paper
• Are we clear about the mechanisms by which biopsy evidence of interstitial fibrosis following cardiac transplantation helps predict late post-transplant coronary artery disease?

  2002cited by this paper
• The role of vitronectin receptor (αvβ3) and tissue factor in the pathogenesis of transplant coronary vasculopathy

  2002cited by this paper
• Immunosuppressive treatment protects against angiotensin II-induced renal damage.

  2002cited by this paper
• Myocardial ischemic-fibrotic injury after human heart transplantation is associated with increased progression of vasculopathy, decreased cellular rejection and poor long-term outcome.

  2002cited by this paper
• The role of vitronectin receptor (alphavbeta3) and tissue factor in the pathogenesis of transplant coronary vasculopathy.

  2002cited by this paper
• Angiotensin II Type 2 Receptor Is Essential for Left Ventricular Hypertrophy and Cardiac Fibrosis in Chronic Angiotensin II–Induced Hypertension

  2001cited by this paper
• High Prevalence of Coronary Atherosclerosis in Asymptomatic Teenagers and Young Adults: Evidence From Intravascular Ultrasound

  2001cited by this paper
• Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

  2001cited by this paper
• A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

  2001cited by this paper
• Proinflammatory actions of angiotensins

  2001cited by this paper
• Role of the renin-angiotensin system in vascular diseases: expanding the field.

  2001cited by this paper
• Regression of left ventricular hypertrophy in human hypertension with irbesartan

  2001cited by this paper
• Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.

  2000cited by this paper
• ACE-gene polymorphism is associated with the development of allograft vascular disease in heart transplant recipients.

  2000cited by this paper
• Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability.

  2000cited by this paper
• Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload

  2000cited by this paper
• Angiotensin II Type 2 Receptors Stimulate Collagen Synthesis in Cultured Vascular Smooth Muscle Cells

  2000cited by this paper
• Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload.

  2000cited by this paper
• Cyclosporin A protects against angiotensin II-induced end-organ damage in double transgenic rats harboring human renin and angiotensinogen genes.

  2000cited by this paper
• Cytokine actions of angiotensin II.

  2000cited by this paper
• New approach in the therapy of chronic rejection? ACE- and AT1-blocker reduce the development of chronic rejection after cardiac transplantation in a rat model.

  2000cited by this paper
• Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling.

  2000cited by this paper
• Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway.

  1999cited by this paper
• Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism.

  1998cited by this paper
• Angiotensin II and gene expression in the kidney.

  1998cited by this paper
• Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression.

  1998cited by this paper
• Interaction of mRNAs for angiotensin II type 1 and type 2 receptors to vascular remodeling in spontaneously hypertensive rats.

  1998cited by this paper
• Salt induces vascular AT1 receptor overexpression in vitro and in vivo.

  1998cited by this paper
• Myocardial angiotensin receptors in human hearts

  1998cited by this paper
• Angiotensin II receptor subtype AT1 and AT2 expression after heart transplantation.

  1998cited by this paper
• Differential distribution of angiotensin AT2 receptors in the normal and failing human heart.

  1998cited by this paper
• Donor ACE gene polymorphism: a genetic risk factor for accelerated coronary sclerosis following cardiac transplantation.

  1998cited by this paper
• Selective downregulation of the angiotensin II AT1-receptor subtype in failing human ventricular myocardium.

  1997cited by this paper
• Differential Distribution of Angiotensin AT 2 Receptors in the Normal and Failing Human Heart 1

  1997cited by this paper
• The critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice.

  1997cited by this paper
• AT1 and AT2 angiotensin receptor gene expression in human heart failure.

  1997cited by this paper
• Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors.

  1997cited by this paper
• Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism.

  1997cited by this paper
• Candesartan cilexetil reduces chronic renal allograft injury in Fisher → Lewis rats

  1997cited by this paper
• Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model. A comparative study with captopril.

  1996cited by this paper
• Angiotensin II-induced progression of neointimal thickening in the balloon-injured rat carotid artery is AT1 receptor mediated.

  1996cited by this paper
• Regulation, chamber localization, and subtype distribution of angiotensin II receptors in human hearts.

  1995cited by this paper
• Alterations of angiotensin II receptor contents in hypertrophied hearts.

  1995cited by this paper
• Occult and frequent transmission of atherosclerotic coronary disease with cardiac transplantation. Insights from intravascular ultrasound.

  1995cited by this paper
• Incidence and progression of transplant coronary artery disease over 1 year: results of a multicenter trial with use of intravascular ultrasound. Multicenter Intravascular Ultrasound Transplant Study Group.

  1995cited by this paper
• Cardiac allograft atherosclerosis in the rat. The effect of histocompatibility factors, cyclosporine, and an angiotensin-converting enzyme inhibitor.

  1994cited by this paper
• Influence of graft rejection on incidence of accelerated graft coronary artery disease: a new approach to analysis.

  1993cited by this paper
• Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart.

  1993cited by this paper
• Captopril Reduces Graft Coronary Artery Disease in a Rat Heterotopic Transplant Model

  1993cited by this paper
• Characterization of angiotensin II receptor subtypes in the rat spleen.

  1992cited by this paper
• Cardiac allograft vasculopathy: relationship with acute cellular rejection and histocompatibility.

  1992cited by this paper
• The influence of rejection episodes on the development of coronary artery disease after heart transplantation.

  1990cited by this paper
• A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation.

  1990cited by this paper
• Prevalence of accelerated coronary artery disease in heart transplant survivors. Comparison of cyclosporine and azathioprine regimens.

  1989cited by this paper
• Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone.

  1987cited by this paper
• Prediction and Entropy

  1985cited by this paper
• The meaning and use of the area under a receiver operating characteristic (ROC) curve.

  1982cited by this paper
• National Heart, Lung, and Blood Institute Coronary Artery Surgery Study. A multicenter comparison of the effects of randomized medical and surgical treatment of mildly symptomatic patients with coronary artery disease, and a registry of consecutive patients undergoing coronary angiography.

  1981cited by this paper
• Binding sites for angiotensin II in human mononuclear leucocytes.

  1978cited by this paper

• Angiotensin‐converting enzyme inhibitor therapy after heart transplant: From molecular basis to clinical effects

  2022cites this paper
• ACE2 and ACE in acute and chronic rejection after human heart transplantation.

  2019cites this paper
• Outpatient Management and Long-Term Complications in Heart Transplantation

  2017cites this paper
• Current diagnostic and treatment strategies for cardiac allograft vasculopathy

  2015cites this paper
• Cardiac allograft immune activation: current perspectives

  2014cites this paper
• Immunosuppression following heart transplantation: prospects and challenges.

  2014cites this paper
• Transplant Research and Risk Management

  2014cites this paper
• Identification of non-HLA antibodies in ventricular assist device recipients

  2013cites this paper
• Endothelial Dysfunction and Cardiac Allograft Vasculopathy

  2013cites this paper
• 112 Identification of Non-HLA Antibodies in Ventricular Assist Device Recipients

  2012cites this paper
• Endothelial dysfunction in cardiac allograft vasculopathy: potential pharmacological interventions.

  2010cites this paper
• Treatment with telmisartan attenuates graft arteriosclerosis in murine cardiac allografts.

  2010cites this paper
• Genomics, transcriptional profiling, and heart failure.

  2009cites this paper
• Recipient genotype is a predictor of allograft cytokine expression and outcomes after pediatric cardiac transplantation.

  2009cites this paper
• Eprosartan in the Primary Prevention of Cardiac Allograft Vascular Disease: A Double-Blind Prospectively Randomized Study using Intravascular Ultrasound

  2008cites this paper
• Late ventricular remodeling in non-reperfused acute myocardial infarction in humans is predicted by angiotensin II type 1 receptor density on blood platelets.

  2008cites this paper
• Cardiac allograft vasculopathy and insulin resistance--hope for new therapeutic targets.

  2007cites this paper
• Cardiac Allograft Vasculopathy: Differences in De Novo and Maintenance Heart Transplant Recipients

  2006cites this paper
• Relation of coronary hypersensitivity to serotonin in cardiac transplant recipients to vessel wall morphology and effect of vitamin C.

  2006cites this paper
• Progress in heart transplantation.

  2005cites this paper
• Role of intravascular ultrasound in the evaluation of therapeutic interventions in coronary atherosclerosis Related review: Role of CETP inhibitors in the treatment of dyslipidemia (pp 631–636)

  2004cites this paper